Podium Session 4: Bladder and Prostate Cancer

Session IV: Prostate Prostate cancer and imaging

Prostate cancer’s incidence, prevalence, etiology, and risk factors, and the influence of clinical trials on imaging technology development are discussed. One in seven Western men older than 70 will develop prostate cancer. The advent of prostate-specific antigen (PSA) screening means most men will now be diagnosed with early disease (85% not palpable on digital rectal exam (DRE), fewer grade 8...

The impact of benign prostatic hyperplasia on bladder volume in radiotherapy of prostate cancer

Background: Benign prostatic hyperplasia (BPH) is a common disease among older men and many patients with prostate cancer (PC) also have BPH. External beam radiation therapy (EBRT) is one of the important treatments for PC, nevertheless, few studies have analyzed the effect of BPH on EBRT. We tried to know the risk of bladder toxicity by analyzing the bladder volume variability in patients with...

Double Urogenital Cancer: Bladder and Prostate Cancer – Case Report

Death receptor 4 and bladder cancer risk.

Tumor necrosis factor-related apoptosis-inducing ligand stimulates the extrinsic apoptoticpathway by binding to death receptors 4 (DR4) and 5 (DR5). In DR4 exon 4, a C-->G polymorphism at amino acid 626 located immediately 3' to one of the main receptor ligand interface regions, results in a threonine-->arginine change. We found that the DR4 exon 4 G/G genotype was associated with an overall de...

The effects of volumetric changes on radiation doses of the rectum and bladder during radiotherapy in patients with prostate cancer

Background: In prostate radiotherapy, changes in the volume of the bladder and rectum can influence dose delivery. In this study, cone-beam computerised tomography (CBCT) imaging was used to assess volumetric, and corresponding radiation dosimetric changes, for the bladder and rectum in patients with prostate cancer treated using VMAT. Materials and Methods: Treatment planning computed tomograp...